Multiple Sclerosis — Description of Adherence to the Main Preventive Health Campaigns of Persons With Multiple Sclerosis
Citation(s)
Barrett MW, Roberts B Preventive Screening in People with Multiple Sclerosis. Int J MS Care. 2010;12:168-176.
Beier M, D'Orio V, Spat J, Shuman M, Foley FW Alcohol and substance use in multiple sclerosis. J Neurol Sci. 2014 Mar 15;338(1-2):122-7. doi: 10.1016/j.jns.2013.12.029. Epub 2013 Dec 27.
Bisson EJ, Ekuma O, Marrie RA, Leslie WD, Finlayson ML Factors associated with receiving bone mineral density screening among people with multiple sclerosis. Mult Scler Relat Disord. 2019 Feb;28:305-308. doi: 10.1016/j.msard.2019.01.022. Epub 2019 Jan 8.
Diab ME, Johnston MV Relationships between level of disability and receipt of preventive health services. Arch Phys Med Rehabil. 2004 May;85(5):749-57.
Dobos K, Healy B, Houtchens M Access to Preventive Health Care in Severely Disabled Women with Multiple Sclerosis. Int J MS Care. 2015 Jul-Aug;17(4):200-5. doi: 10.7224/1537-2073.2013-046.
Dupont WD Power calculations for matched case-control studies. Biometrics. 1988 Dec;44(4):1157-68.
EuroQol Group EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199-208.
Hayes JH, Barry MJ Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA. 2014 Mar 19;311(11):1143-9. doi: 10.1001/jama.2014.2085. Review.
Hohol MJ, Orav EJ, Weiner HL Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology. 1995 Feb;45(2):251-5.
Melamed E, Lee MW Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies. Front Immunol. 2020 Jan 10;10:2954. doi: 10.3389/fimmu.2019.02954. eCollection 2019. Review.
Naing L, Winn T, Rusli BN Practical issues in calculating the sample size for prevalence studies. Arch Orofacial Sci 2006;1:9-14.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
